Research programme: BRPF1 protein inhibitors - BayerAlternative Names: BAY-140; BAY-496; Bromodomain and PHD finger-containing 1 protein inhibitors - Bayer
Latest Information Update: 05 May 2016
At a glance
- Originator Bayer
- Class Small molecules
- Mechanism of Action BRPF1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer